FDA panel snubs 'partial' Rx-to-OTC switch for Merck's Singulair
This article was originally published in Scrip
The FDA's Nonprescription Drugs Advisory Committee (NDAC) on 2 May advised against permitting Merck to market Singulair (montelukast), a leukotriene receptor antagonist, as an over-the-counter (OTC) medicine for US adults 18 or older to treat allergies – raising concerns patients with asthma of all ages, including pediatrics, would be tempted to use the product off-label to self-treat rather than seeking the care of a physician for their condition.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.